Antagonist peptides to the C5A chemotactic function of vitamin D binding protein
AssigneeThe Research Foundation of State University of New York
InventorsRichard R. Kew, Jianhua Zhang
Life of this patent
Estimating the term…
Abstract
It has been demonstrated that one of Vitamin D Binding Protein (DBP) biological functions is to enhance the chemotactic activity of C5a and C5a des Arg. The present invention has found that peptides having sequences that substantially correspond to a specific region in the N-terminal domain I of DBP can block the DBP enhancement of C5a or C5a des Arg chemotactic activity. Based in this discovery the present invention provides DBP antagonist peptides and the use thereof for the treatment C5a or C5a des Arg-mediated disorders.
Claims4
An isolated Vitamin D Binding Protein (DBP) antagonist peptide consisting of EAFRKDPKEYANQFMWEYST (SEQ ID NO:
- 1).
A Vitamin D Binding Protein (DBP) antagonist peptide consisting of an amino acid sequence selected from the group consisting of:
- (i)
- EAFRKDPKEYANQFMWEYSTNYG;
- (SEQ ID NO:
- 3)
- (ii)
- NYGQAPLSLLVSYTKSYLSMVGS;
- (SEQ ID NO:
- 4)
- (iii)
- EAFRKDPKEYANQFMWEYS;
- (SEQ ID NO:
- 5)
- (iv)
- EAFRKDPKEYANQFM;
- (SEQ ID NO:
- 6)
- (v)
- DPKEYANQFMWEYST;
- (SEQ ID NO:
- 7)
- (vi)
- EAFRKDPKEYAN;
- (SEQ ID NO:
- 8)
- (vii)
- DPKEYANQFMWE;
- (SEQ ID NO:
- 9)
- (viii)
- NQFMWEYSTNYG;
- (SEQ ID NO:
- 10)
- (ix)
- YANQFMWEYST;
- (SEQ ID NO:
- 11)
- (x)
- EAFRKDPKEY;
- (SEQ ID NO:
- 12)
- (xi)
- ANQFMWEYST;
- (SEQ ID NO:
- 13)
- (xii)
- DPKEYANQFM;
- (SEQ ID NO:
- 14)
- (xiii)
- NQFMWEYST;
- (SEQ ID NO:
- 15)
- (xiv)
- NQFMWEYS;
- (SEQ ID NO:
- 16)
- (xv)
- QFMWEYST;
- (SEQ ID NO:
- 17)
- (xv)
- NQFMWEY;
- (SEQ ID NO:
- 18)
- (xvi)
- QFMWEYS;
- (SEQ ID NO:
- 19)
- (xvii)
- FMWEYST;
- (SEQ ID NO:
- 20)
- (xviii)
- EAFRKD;
- (SEQ ID NO:
- 21)
- (xix)
- KEYANQ;
- (SEQ ID NO:
- 22)
- (xx)
- YANQFM;
- (SEQ ID NO:
- 23)
- (xxi)
- ANQFMW;
- (SEQ ID NO:
- 24)
- (xxii)
- NQFMWE;
- (SEQ ID NO:
- 25)
- (xxiii)
- QFMWEY;
- (SEQ ID NO:
- 26)
- (xxiv)
- FMWEYS;
- (SEQ ID NO:
- 27)
- (xxv)
- EAFRK;
- (SEQ ID NO:
- 28)
- (xxvi)
- AFRKD;
- (SEQ ID NO:
- 29)
- (xxvii)
- DPKEY;
- (SEQ ID NO:
- 30)
- (xxviii)
- ANQFM;
- (SEQ ID NO:
- 31)
- (xxix)
- WEYST;
- (SEQ ID NO:
- 32)
- (xxxi)
- YANQF;
- (SEQ ID NO:
- 33)
- (xxxii)
- ANQFM;
- (SEQ ID NO:
- 34)
- (xxxiii)
- NQFMW;
- (SEQ ID NO:
- 35)
- (xxxiv)
- QFMWE;
- (SEQ ID NO:
- 36)
- (xxxv)
- FMWEY;
- (SEQ ID NO:
- 37)
- and
- (xxxvi)
- MWEYS.
- (SEQ ID NO:
- 38)
A pharmaceutical composition comprising the isolated peptide of SEQ ID NO:
- 1 and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.